Company intelligence / Profile preview

HighCape Capital Acquisition

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

HighCape Capital Acquisition was a healthcare-focused special purpose acquisition company (SPAC) formed to identify and merge with a business in life sciences or related industries. The company completed its IPO in 2020 and in June 2021 closed its business combination with Quantum-Si, a proteomics tools company. Following the transaction, HighCape changed its name to Quantum-Si and its Nasdaq ticker changed from CAPA to QSI. HighCape itself did not operate a therapeutic pipeline, develop drugs, or provide commercial healthcare products or services apart from serving as a publicly traded acquisition vehicle.

Industry: Investors

Partnerships

Quantum-Si

Beyond the preview

Go deeper on HighCape Capital Acquisition.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HighCape Capital Acquisition.

Explore the full profile